SLRX Prakiraan volume dodolan Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Inc - logo grafis emiten SLRX

Salarius Pharmaceuticals relies on grants to develop epigenetic treatments for rare tumors, while FDA orphan drug status ensures a future monopoly. The company's future sales metric demonstrates market equilibrium, where 0.00 serves as the final level mark. Strategic alliances with oncology centers are expanding pediatric cancer therapies, significantly enhancing the company's investment attractiveness for future merger and acquisition deals.

Prakiraan pendapatan perusahaan: Salarius Pharma (SLRX) kanggo 04.07.2022 - 08.01.2026

Rincian metrik keuangan lan pasar Salarius (SLRX)

- nilai saham lan prakiraan konsensus rega:
Analisis dhasar perusahaan:salariuspharma.com SLRX
Produk mawa merek Salarius Pharmaceuticals Inc

An investment audit of the issuer requires a thorough assessment of future cash flow potential prior to asset acquisition. This metric aggregates market expectations for total commercial revenues, measuring the liquidity and resilience of the business model. For Salarius Pharmaceuticals (SLRX), this calculation reflects the commercial success of genetic research in the therapy of rare oncological diseases. Stability or stagnation in the current sales forecast level signals the degree of market confidence in bringing drugs to the monetization stage.

Analisis perusahaan pesaing

Prakiraan volume dodolan ONC|HALO (Halozyme) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan RVMD (revmed.com)|Dodolan mangsa ngarep perusahaan Ascentage (AAPG)|CGON: Volume dodolan mangsa ngarep perusahaan|Volume dodolan sing dikarepake perusahaan UroGen Pharma Ltd.|BCAX: Prakiraan volume dodolan|PSNL - Dodolan mangsa ngarep perusahaan|ERAS (Erasca Oncology) - Prakiraan volume dodolan|Prakiraan volume dodolan Delcath Systems, Inc.|Prakiraan pendapatan perusahaan ymabs.com (YMAB)|Prakiraan pendapatan perusahaan AURA (Aura Biosciences, Inc.)|Candel Therapeutics - Volume dodolan mangsa ngarep perusahaan|Accuray Inc. (ARAY) - Volume dodolan sing dikarepake perusahaan|SELLAS Life Sciences Group, Inc. - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan ACTU (Actuate Therapeutics, Inc.)|Citius Oncology (CTOR) - Prakiraan pendapatan perusahaan|HURA - Dodolan mangsa ngarep perusahaan|TARA (Protara Therapeutics, Inc.) - Prakiraan volume dodolan|Prakiraan volume dodolan Fate Therapeutics Inc|Prakiraan volume dodolan WHWK|Prakiraan volume dodolan TScan Therapeutics Inc (TCRX)|Prakiraan pendapatan perusahaan championsoncology.com CSBR|XBIT - Volume dodolan mangsa ngarep perusahaan|CVM - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan OSTX (OS Therapies)|RADX: Prakiraan volume dodolan|Artiva Biotherapeutics Inc. - Pendapatan mangsa ngarep perusahaan|ANL (Adlai Nortye) - Prakiraan volume dodolan|Prakiraan volume dodolan verupharma.com|Volume dodolan mangsa ngarep perusahaan TPST (tempesttx.com)|Volume dodolan mangsa ngarep perusahaan Xilio Therapeutics Inc XLO|Prakiraan volume dodolan RENB (Enochian BioSciences)|Mural Bio - Prakiraan pendapatan perusahaan|KAPA - Prakiraan pendapatan perusahaan|OnKure Therapeutics (OKUR) - Volume dodolan mangsa ngarep perusahaan|GDTC: Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Curis Corp (CRIS)|APLM (apollomicsinc.com) - Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Tharimmune Corp (THAR)|Prakiraan volume dodolan ADVB|GNPX - Volume dodolan sing dikarepake perusahaan|Prakiraan pendapatan perusahaan calidibio.com CLDI|SBFM - Volume dodolan mangsa ngarep perusahaan|XBIO - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Kitov Pharma|AON (AONC) - Prakiraan pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan BeiGene|Prakiraan pendapatan perusahaan checkpointtx.com|Prakiraan pendapatan perusahaan ELEV (Elevation Oncology)|Prakiraan volume dodolan ICAD|Ikena Oncology - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Notable Labs, Ltd. NTBL|VIRX: Prakiraan pendapatan perusahaan|MOR - Prakiraan pendapatan perusahaan|NAYA Bio (NAYA) - Volume dodolan mangsa ngarep perusahaan|AAPGV: Prakiraan volume dodolan